

BLOOD-BASED TESTING HELPS PHYSICIANS QUICKLY AND ACCURATELY RULE OUT MALIGNANCY FOR PATIENTS WITH AN INCIDENTAL LUNG NODULE

The Nodify XL2TM test is intended for patients with:

- A new lung nodule diagnosis code (R91.1 or R91.8)
- A nodule of concern with a diameter between 8-30mm
- A risk of malignancy of 50% or less, calculated using the solitary pulmonary nodule calculator
- 40 years old or greater
- Patients who have never had lung cancer and do not have a history of cancer within the last 5 years

BENEFITS:

- Designed to help identify likely benign nodules with a simple blood-based test
- Stratifies risk of malignancy prior to bronchoscopy
- Post-Nodify XL2 risk of malignancy results can be readily incorporated into management workflows and guidelines
- Testing covered by Medicare and Medicaid

